Syndax Pharmaceuticals (SNDX) Soars 13.9% Despite Q4 Loss

Syndax Pharmaceuticals, Inc. (SNDX) surged 13.9% in pre-market trading on April 8, 2025, marking a significant uptick in investor interest.

Syndax Pharmaceuticals reported a Q4 loss, falling short of revenue estimates. The company's earnings and revenue surprises were -1.85% and 65.45%, respectively, indicating a challenging quarter.

Shares of Syndax Pharmaceuticals have experienced a significant decline, dropping over 50% due to the lower complete response rate of Revuforj compared to Kura Oncology's ziftomenib in treating relapsed/refractory NPM1-mutated acute myeloid leukemia.

Bryce Point Capital LLC acquired a new stake in Syndax Pharmaceuticals during the fourth quarter, demonstrating continued institutional interest in the company.